首页> Therapeutic advances in neurological disorders> Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.

Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.

导出 OA

翻译打印收藏纠错

第一作者： Annette,Wundes

第一单位： Department of Neurology, University of Washington Medical Center, Seattle, WA, USA.

作者： Annette,Wundes ^[1] ; Sibyl,Wray ^[2] ; Ralf,Gold ^[3] ; Barry A,Singer ^[4] ; Elzbieta,Jasinska ^[5] ; Tjalf,Ziemssen ^[6] ; Jerome,de Seze ^[7] ; Pavle,Repovic ^[8] ; Hailu,Chen ^[9] ; Jerome,Hanna ^[10] ; Jordan,Messer ^[11] ; Catherine,Miller ^[9] ; Robert T,Naismith ^[12]

作者单位： Department of Neurology, University of Washington Medical Center, Seattle, WA, USA. ^[1] Hope Neurology MS Center, Knoxville, TN, USA. ^[2] Department of Neurology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany. ^[3] The MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO, USA. ^[4] Collegium Medicum UJK and Clinical Center, RESMEDICA, Kielce, Poland. ^[5] Center of Clinical Neuroscience, Carl Gustav Carus University Hospital, Dresden, Germany. ^[6] Strasbourg University Hospital and Clinical Investigation Center, INSER 1434, Strasbourg, France. ^[7] Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA. ^[8] Biogen, Cambridge, MA, USA. ^[9] Biogen, Maidenhead, UK. ^[10] Biogen, 225 Binney Street, Cambridge, MA 02142-1031, USA. ^[11] Washington University School of Medicine, St. Louis, MO, USA. ^[12]

关键词 clinical trial diroximel fumarate disease-modifying therapy gastrointestinal relapsing-remitting multiple sclerosis

DOI 10.1177/1756286421993999

PMID 33796143

发布时间 2022-04-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交